Company Overview and News

 
Centaurus is the ASX Volume Leader on potential from the world‐class Carajás Mineral Province

2017-11-08 proactiveinvestors.com.au
Centaurus Metals Ltd (ASX:CTM) is the ASX's most active stock, trading 99 million shares in the first 90 minutes of trade, while gaining 40% to $0.007.

 
Centaurus Metals raising $2.5M for Brazilian projects via rights issue

2017-08-09 proactiveinvestors.com.au
Centaurus Metals (ASX:CTM) is raising $2.5 million for its explorations programs at the Serra Misteriosa Gold Project and the Salobo West Copper‐Gold Project, both in Brazil.

 
Centaurus Metals and Queensland Bauxite in hunt for top ASX % Gainer status

2017-08-09 proactiveinvestors.com.au
Centaurus Metals Ltd's (ASX:CTM) shares have gained 33% to $0.004 following a significantly oversubscribed rights issue which raised $2.5 million.

 
Centaurus Metals begins maiden drill program at Misteriosa Gold

2017-05-19 proactiveinvestors.com.au
Centaurus Metals (ASX:CTM) has commenced its maiden diamond drill program at the highly prospective Serra Misteriosa Gold Project in Northern Brazil.

 
Centaurus Metals ready to begin major gold exploration program in Brazil

2016-10-25 proactiveinvestors.com.au
The Pará exploration package was secured via an agreement with the company’s strategic alliance partner, Terrativa Minerais SA.

 
Centaurus Metals Ltd to start maiden drilling campaign at Brazil gold project

2016-07-19 proactiveinvestors.com.au
Centaurus Metals Ltd (ASX:CTM) is set to commence drilling at its Mombuca Gold Project in Brazil, where it has recently identified significant gold targets from geophysical surveys. The program will include 2,500 metres of diamond drilling and will test multiple strong geophysical and geochemical targets to a depth of 300 metres below surface. The first phase of drilling will target the ITZ Prospect, a 1.

 
Centaurus enters potash JV

2016-06-17 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Centaurus enters potash JV

2016-06-17 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Centaurus Metals Ltd gets ready to raise

2016-06-14 proactiveinvestors.com.au
Centaurus Metals Ltd (ASX:CTM) recently changed its focus by entering into a strategic alliance with the private Brazilian exploration company Terrativa Minerais SA, to help diversify the company away from iron ore. The alliance has helped in the acquisition of the Mombuca Project in Brazil, which has the potential for high-grade gold mineralisation. The halt will remain in place until the opening of trade on Friday 17th June 2016, or earlier if an announcement is made to the market.

 
Appendix 3B

2016-05-03 asx.com.au

 
Change of Company Secretary

2016-05-03 asx.com.au

 
Quarterly Activities Report

2016-04-27 asx.com.au

 
Quarterly Cashflow Report

2016-04-27 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...